EXoZymes Inc
EXOZ
Company Profile
Business description
EXoZymes Inc is focused on using a biomanufacturing platform to create valuable biochemicals, including Active Pharmaceutical Ingredients or APIs, biofuels, food flavors, and cosmetics, offering a sustainable alternative to traditional chemical production methods. The company believes its platform will enable scalable production of chemical molecules found in nature in a process that is alternative to and more environmentally friendly and sustainable than the typical methods used today, such as chemical synthesis, natural extraction, and synthetic biology.
Contact
750 Royal Oaks Drive
Suite 106
MonroviaCA91016
USAT: +1 626 415-1488
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
32
Stocks News & Analysis
stocks
Investors punish this ASX player after acquisition
We think the floundering stock price is not reflective of underlying asset value.
stocks
Revenue growth on track for undervalued ASX healthcare stock
Near-term cost growth does not change our long-term view.
stocks
Sales shine but broader macro outlook darkens for this ASX share
US stores are struggling, but our investment thesis hinges on the Australian rollout.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,155.80 | 34.00 | 0.37% |
| CAC 40 | 8,259.60 | 13.81 | 0.17% |
| DAX 40 | 23,803.95 | 3.04 | -0.01% |
| Dow JONES (US) | 47,940.06 | 245.74 | -0.51% |
| FTSE 100 | 10,600.53 | 2.95 | -0.03% |
| HKSE | 25,893.54 | 141.14 | 0.55% |
| NASDAQ | 22,888.93 | 66.52 | 0.29% |
| Nikkei 225 | 56,924.11 | 1,028.79 | 1.84% |
| NZX 50 Index | 13,181.44 | 92.37 | -0.70% |
| S&P 500 | 6,817.84 | 6.82 | -0.10% |
| S&P/ASX 200 | 8,960.60 | 36.20 | 0.41% |
| SSE Composite Index | 3,986.22 | 20.05 | 0.51% |